22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
In 2019, we saw significant activity in state legislatures passing employment-related laws in areas ...
Read More >
Seyfarth Synopsis: On December 19, 2019, the U.S. Treasury issued final Qualified Opportunity Zone r...
Read More >
With the California Consumer Privacy Act of 2018 (CCPA) set to take effect on January 1, 2020, Calif...
Read More >
The #MeToo movement has brought public awareness to claims concerning pay disparity based on gender....
Read More >
President Trump’s October 9, 2019 overtures landed as music to the ears of many a grizzled immigrat...
Read More >
On February 2, 2020, Law of Ukraine no. 378-I? entered into force and significantly reduced the amou...
Read More >